CBM has been identified in a nonpsychotropic variety of hemp(Taglialatela-Scafati et al., 2010). It targets the pparγ receptor, acting as a pparγ  agonist and regulating insulin pathways, making CBM a potential candidate to treat insulin-resistance related disorders (Iannotti et al., 2014).

References

Iannotti, F. A., Hill, C. L., Leo, A., Alhusaini, A., Soubrane, C., Mazzarella, E., Russo, E., Whalley, B. J., Di Marzo, V., & Stephens, G. J. (2014). Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: Potential for the treatment of neuronal hyperexcitability. ACS Chemical Neuroscience, 5(11), 1131–1141. https://doi.org/10.1021/cn5000524

Taglialatela-Scafati, O., Pagani, A., Scala, F., De Petrocellis, L., Di Marzo, V., Grassi, G., & Appendino, G. (2010). Cannabimovone, a cannabinoid with a Rearranged Terpenoid Skeleton from Hemp. European Journal of Organic Chemistry, 2010(11), 2067–2072. https://doi.org/10.1002/ejoc.200901464